Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Teva
AstraZeneca
Deloitte
Merck
UBS
Argus Health
Boehringer Ingelheim
McKesson

Generated: December 12, 2017

DrugPatentWatch Database Preview

Bristol Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL, and what generic alternatives to BRISTOL drugs are available?

BRISTOL has one hundred and ten approved drugs.

There are twenty-four US patents protecting BRISTOL drugs and there have been three Paragraph IV challenges on BRISTOL drugs in the past three years.

There are six hundred and sixty-three patent family members on BRISTOL drugs in fifty-eight countries and two hundred and seven supplementary protection certificates in fifteen countries.

Summary for Bristol

International Patents:663
US Patents:24
Tradenames:87
Ingredients:74
NDAs:110
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bristol-myers SquibbEVOTAZatazanavir sulfate; cobicistatTABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSTILBETINdiethylstilbestrolTABLET;ORAL004056-009Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSPRYCELdasatinibTABLET;ORAL021986-004May 30, 2008ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbNARCANnaloxone hydrochlorideINJECTABLE;INJECTION071083-001Jul 28, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
BristolBETAPEN-VKpenicillin v potassiumTABLET;ORAL061150-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSUSTIVAefavirenzTABLET;ORAL021360-001Feb 1, 2002DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbSUSTIVAefavirenzCAPSULE;ORAL020972-002Sep 17, 1998DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Bristol Myers SquibbPRAVACHOLpravastatin sodiumTABLET;ORAL019898-002Oct 31, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbELIQUISapixabanTABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbSTILBETINdiethylstilbestrolTABLET;ORAL004056-007Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers SquibbSUSTIVAefavirenzCAPSULE;ORAL020972-001Sep 17, 1998► Subscribe► Subscribe
Bristol Myers SquibbHYDREAhydroxyureaCAPSULE;ORAL016295-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Bristol Myers SquibbMONOPRIL-HCTfosinopril sodium; hydrochlorothiazideTABLET;ORAL020286-002Nov 30, 1994► Subscribe► Subscribe
Bristol Myers SquibbZERITstavudineCAPSULE;ORAL020412-004Jun 24, 1994► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineFOR SOLUTION;ORAL020155-006Oct 9, 1991► Subscribe► Subscribe
Bristol Myers SquibbMONOPRILfosinopril sodiumTABLET;ORAL019915-004Mar 28, 1995► Subscribe► Subscribe
Bristol Myers SquibbVIDEX ECdidanosineCAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineTABLET, CHEWABLE;ORAL020154-003Oct 9, 1991► Subscribe► Subscribe
Bristol Myers SquibbBUSPARbuspirone hydrochlorideTABLET;ORAL018731-004Apr 22, 1996► Subscribe► Subscribe
Bristol Myers SquibbVIDEXdidanosineTABLET, CHEWABLE;ORAL020154-005Oct 9, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRISTOL drugs

Drugname Dosage Strength Tradename Submissiondate
apixabanTablets2.5 mg and 5 mgELIQUIS12/28/2016
efavirenzCapsules50 mg, 100 mg and 200 mgSUSTIVA11/3/2016
naloxone hydrochlorideNasal Spray4 mg/sprayNARCAN7/15/2016
dasatinibTablets80 mg and 140 mgSPRYCEL6/17/2011
dasatinibTablets80 mg and 140 mgSPRYCEL6/16/2011
dasatinibTablets20 mg, 50 mg, 70 mg and 100 mgSPRYCEL6/28/2010
entecavirTablets0.5 mg and 1 mgBARACLUDE6/14/2010
atazanavir sulfateCapsules100 mg and 150 mgREYATAZ3/19/2010
atazanavir sulfateCapsules200 mgREYATAZ2/16/2010
atazanavir sulfateCapsules300 mgREYATAZ7/20/2009
efavirenzTablets600 mgSUSTIVA4/9/2009
pravastatin sodiumTablets30 mgPRAVACHOL6/1/2005
didanosineDelayed-release Capsules200 mg, 250 mg and 400 mgVIDEX EC6/1/2004

Non-Orange Book Patents for Bristol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,005,435Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
9,227,961Hepatitis C virus inhibitors► Subscribe
6,989,391Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
8,486,942Modulators of pharmacokinetic properties of therapeutics► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,242,270Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Drugs

Country Document Number Estimated Expiration
Singapore183007► Subscribe
World Intellectual Property Organization (WIPO)2009020828► Subscribe
Australia6263298► Subscribe
Israel144910► Subscribe
Portugal2487163► Subscribe
Hong Kong1143144► Subscribe
Australia2007286222► Subscribe
European Patent Office1610780► Subscribe
Germany69841972► Subscribe
Norway328558► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
01C/001Belgium► SubscribePRODUCT NAME: EFAVIRENZ; NATL. REGISTRATION NO/DATE: EU/1/99/110/001 19990604; FIRST REGISTRATION: CH 54908 01 19981120
2011012,C1427415Lithuania► SubscribePRODUCT NAME: APIXABANUM; REGISTRATION NO/DATE: EU/1/11/691/001 - EU/1/11/691/005, 0110518
/2004Austria► SubscribePRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
13/034Ireland► SubscribeAPPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
C0006France► SubscribePRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
0150003 00128Estonia► SubscribePRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014
275Luxembourg► SubscribeCERTIFICATE TITLE: ENTECAVIR ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BARACLUDE); FIRST REGISTRATION: 20060626
/2008Austria► SubscribePRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408
00357Netherlands► SubscribePRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Johnson and Johnson
Cantor Fitzgerald
Argus Health
AstraZeneca
Healthtrust
Harvard Business School
Teva
Medtronic
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot